Sanofi Stock News

Sanofi's CEO is under pressure to tell investors how much more he will spend on research and development (R&D) and what the likely pay-offs will be, as he seeks to boost a pipeline of future drugs and

Here are three undervalued stocks with promising growth potential and high-quality A-rated balance sheets. It's just one of three incredible opportunities that combine to create a 16% annual return po

Limited pipeline catalysts until 2025 mean a "show me" story status. Higher R&D costs and uncertainty for the future. A new spin-off in the consumer division with no 2025 profitability targets. Sanofi

Sanofi plans to file for U.S. approval of wider use of its anti-inflammatory drug Dupixent against "smoker's lung", also known as COPD, after a second large trial showed significant benefits.

The mother of two autistic children in France has lodged a legal complaint for endangering life after she suspected she was exposed to airborne emissions from Sanofi's Depakine epilepsy drug plant, th

The CDC's move to increase availability of Beyfortus, a monoclonal antibody from Sanofi and AstraZeneca, comes as RSV cases rise in some parts of the country.

The U.S. Centers for Disease Control and Prevention said on Thursday it has released more than 77,000 additional doses of Sanofi and AstraZeneca's respiratory syncytial virus (RSV) drug Beyfortus.

While many Wall Street firms are suggesting short Treasury paper and money markets now, for long-term investors looking for growth and income, healthcare is the place to be for the rest of 2023 and li

TEVA reports decent third-quarter results. The company raises its revenue guidance for 2023 for the second time this year while keeping the EPS range intact.

French prosecutors have opened a preliminary investigation into multinational pharmaceutical company Sanofi over possible market manipulation.

Pharmaceutical stocks aren't having quite the banner year they've had in the past. Notably, two large pharmaceutical companies recently plunged to 52-week lows on their earnings results.

Sanofi's third-quarter results weren't great, and the company announced a business separation. The biotech will lower its operating income margin target for 2025, which scared off many investors.

The Health Care Select Sector SPDR Fund NYSEARCA: XLV was down 3.81% in the past month and 8.03% in the past three months. The latest round of pharmaceutical stock earnings isn't helping sector perfor

MeiraGTx Holdings PLC (NASDAQ:MGTX) shares gained more than 25% after it announced Sanofi SA (ADR) (NYSE:SNY), a pharma giant best known for its vaccines, is purchasing 4 million of the gene company's

Sanofi (SNY) shares are trending higher after plummeting last Friday, after the pharmaceutical company missed third-quarter earnings expectations, losing over $21 billion in market value. Sanofi annou